Topics

Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

10:24 EDT 15 Aug 2019 | SCRIP

US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory...

      

Related Stories

 

Original Article: Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

NEXT ARTICLE

More From BioPortfolio on "Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions"

Quick Search

Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Tuberculosis TB
Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. Over nine million new cases of TB, and nearly two million deaths from TB, are estimated to occur around the world every year, and new inf...